Common TitleSUPPORT
Official Title A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
Phase Phase III
ClinicalTrials.gov NCT00727597
Treatments
Fosamprenavir
, Fosamprenavir
Tradename:LexivaOther Names:FPVClass:Protease Inhibitors (PI)Efavirenz
Efavirenz
Tradename:SustivaOther Names:EFVClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
Non-IndustryGeorgetown University
References
- Kumar P, DeJesus E, Huhn G, et al. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis. 2013;13:269.